Approved for treating Cryopyrin-Associated autoinflammatory syndromes (CAPS)
Both
Neither
CAPS: presenting symptoms and treatment
Symptoms include recurring fever, hive-like rash as well as joint pain and swelling. absent treatment, deafness or amyloidosis may occur, the lateral which may be associated with organ failure.
Treatment: drugs targeting interleukin-1 appear effective; these drugs include anakinra (Kineret), rilonacept (Arcalyst), canakinumab (Ilaris)
Both
Neither
Canakinumab (Ilaris) clinical use/uses:
CAPS
Systemic, active juvenile idiopathic arthritis.
Both
Neither
Canakinumab (Ilaris)
Human IgG1/I-κ monoclonal antibody targeting IL-1β.
Canakinumab binds to IL-1β, preventing binding to IL-1 receptors.
Both
Neither
Canakinumab in preventing IL-1β from binding to IL-1 receptors induces
a reduction in inflammatory response in patients with certain autoimmune disorders.
True
False
FDA approval of canakinumab use/uses:
Two forms of cryopyrin-associated periodic syndrome
Muckle-Wells syndrome
Familial cold autoinflammatory syndrome (FCAS)
Gout
A & B
B & C
A & C
A, B & C
A, B, C & D
Canakinumab has been approved in the US to treat Still's disease (including adult-onset):
True
False
Canakinumab pharmacokinetics:
Subcutaneous administration
Bioavailability about 66%
Both
Neither
Canakinumab may be administered just once monthly while still exhibiting full effectiveness.
True
False
Considered most common adverse effects/effects of interleukin-1 inhibitors:
Injection-site reaction (as much as 40% of patients exhibit this reaction)
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 25 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 76 Drug Therapy for Rheumatoid Arthritis
Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
Waller DG Sampson A Hitchings Ch 38 The
Immune Response and Immunosuppressant Drugs
Medical Pharmacology & Therapeutics 6e Elsevier 2022
Waller DG Sampson A Hitchings Ch 30
Rheumotoid Arthritis, Other Inflammatory Arthrides and
Osteoarthritis Medical Pharmacology & Therapeutics 6e
Elsevier 2022
